MA-BOARD-INTERNATIONAL
20.7.2021 16:02:09 CEST | Business Wire | Press release
Board International, the all-in-one Board Decision-Making Platform vendor, today announced strong Q2 2021 performance, achieving a 45% increase in ARR across the last 12 months.
The company experienced robust levels of growth in Q2 2021, which included a 58% increase in new Software ARR orders compared to the same quarter last year, contributing to a 69% increase in H1 2021. Board has more than 3,000 customers worldwide and welcomed 54 new brands in Q2 2021, including Jhpiego, Zentiva, Evergreen Environmental, and Luye Pharma. Additionally, Board registered a Net Retention Rate of 114%.
During the second quarter of the year, Board announced the addition of Marco Limena to its Board of Directors as Non-Executive Director and Senior Advisor. The company has also hired more than 125 people since the beginning of the year, growing its employee base by 15% to reach a total headcount of 500 employees across 25 countries. These new hires include various industry leaders and experts, including Mr. Christof Majer as Global VP of Alliances & Channel, who will lead partner business strategy, and Mr. Marcel Doppenberg as Sales Director for the Benelux Region, who will drive local growth.
On April 28, Board released Board Spring 21, the latest version of its market-leading Decision-Making Platform. The new version represents a great milestone in the evolution of Board’s technology and empowers organizations to access supercharged performance, unmatched flexibility, rock-solid reliability, and a seamless upgrade path from previous versions. Board continues to replace legacy applications and spreadsheets, driving a new era of decision-making, helping enterprises succeed in a constantly changing reality through greater planning agility and more accurate insights.
During the second quarter, Board also continued to strengthen its position as a leading provider of unified Business Intelligence, Planning, and Predictive Analytics, and its value proposition received significant attention from analysts. Board International was recognized as a March 2021 Gartner Peer Insights Customers’ Choice for Cloud Financial Planning and Analysis (FP&A) Solutions, confirmed as a Market Leader with the Best Portfolio Capabilities in Integrated Planning & Analytics by BARC, and named a Leader in the Customer Experience and Vendor Credibility models in Dresner Advisory’s 2021 Wisdom of Crowds Market Study for both BI and EPM.
"I am very proud of these results, for which I want to congratulate the entire Board team. Our flexible, all-in-one Decision-Making Platform gives organizations a strong competitive advantage. It is the perfect choice for functional planning requirements and also for achieving the ideal state of unifying planning across the enterprise," comments Maurizio Carli, CEO of Board International. "In the second half of the year, we will continue focusing on product innovation to enhance our customer experience and support growing market demand."
About Board
Board is the #1 Decision-Making Platform. Founded in 1994, Board International enables people to have a transformative impact on their business, helping them to intuitively leverage their data in a flexible, all-in-one environment. By unifying Business Intelligence, Planning, and Predictive Analytics, the Board platform allows companies to produce a single, accurate, and complete view of business information, gain actionable insights, and achieve full control of performance across the entire organization. Thanks to Board, global enterprises such as M&S, Coca-Cola, Ricoh, KPMG, Puma, Siemens, and ZF Group have deployed end-to end decision-making applications at a fraction of the time and cost associated with traditional solutions. www.board.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210720005826/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Angelini Pharma and Quiver Bioscience Announce Strategic Research Collaboration and Licensing Agreement to Discover and Advance Novel Therapeutics for Genetic Epilepsies23.2.2026 14:08:00 CET | Press release
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and royalties Collaboration further expands Angelini Pharma’s focus on brain health, building on its deep therapeutic expertise and drug development experience Angelini Pharma, part of the privately owned Angelini Industries, and Quiver Bioscience (“Quiver”), a discovery technology and therapeutics company advancing programs for the treatment of central nervous system (CNS) disorders, announced today that they have entered into a collaboration and licensing agreement to advance novel therapeutics for genetic epilepsies. The collaboration brings together Quiver’s unique drug discovery capabilities, data assets, and AI models with Angelini Pharma’s established expertise in brain health and epilepsy drug development. This press release features multimedia. View the full release here: https://www.busine
Armis Achieves U.S. Department of Defense Impact Level 5 Authorization23.2.2026 14:00:00 CET | Press release
DoD customers can now leverage Armis Centrix™ with enhanced security controls and connectivity Armis, the cyber exposure management & security company, today announced that it has achieved authorization from the U.S. DoD’s Defense Information Systems Agency (DISA) to operate at an Impact Level 5 (IL5). This means that Armis has met strict requirements to manage and secure the DoD’s critical infrastructure, including Controlled Unclassified Information (CUI) systems. “We are committed to helping Federal agencies like the Department of Defense address their toughest cybersecurity challenges,” said Alex Mosher, President and CRO at Armis. “Achieving DISA IL5 authorization is an important milestone for Armis as we continue to support DoD customers in safeguarding critical systems, sensitive data and national security infrastructure from evolving cyber threats.” Armis empowers Federal agencies to build and optimize comprehensive cybersecurity programs with Armis Centrix™, the FedRAMP and DI
IQM, a Global Leader for Quantum Computing, to Become the First Listed European Quantum Company, Through Merger with Real Asset Acquisition Corp.23.2.2026 13:49:00 CET | Press release
Global commercial leader with 21 systems sold to 13 customers to date – including 4 out of the top 10 supercomputing centres globally. Industrial leader with 15 systems delivered (largest number publicly disclosed by selected quantum companies1), 30+ computers built, own chip factory and quantum data centre. The transaction values IQM at a pre-money equity valuation of approximately USD 1.8 billion and makes IQM the first European quantum company to go public. With the close of this transaction, IQM’s cash position expected to exceed USD 450 million.2 Significant business momentum, with at least USD 35 million3 2025 revenue (unaudited) and over USD 100 million bookings / visibility as of year-end 2025. Strong commercial integrations with high-performance computing and enterprise platforms across the quantum/AI value chain such as NVIDIA, Hewlett Packard Enterprise, AWS, Toyo Corporation and Bechtle AG. Technical successes, achieving greater than 99.9% fidelity for single-qubit and two-
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device23.2.2026 13:30:00 CET | Press release
MIUDELLA® is a strategic addition to Organon’s portfolio, strengthening its long‑term commitment to advancing women’s health Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Drug Administration (FDA) approval of MIUDELLA's alternate supply chain entities and certain other conditions. MIUDELLA, the first hormone-free copper IUD approved in the U.S. in the last 40 years, is complementary to Organon’s commercial capabilities and would further Organon’s commitment to building a portfolio of products that meet women’s diverse reproductive health needs. MIUDELLA was approved by the FDA on
Lenovo Unlocks Data Potential with Next Generation of AI-Driven ThinkEdge Solutions23.2.2026 12:00:00 CET | Press release
New ThinkEdge devices deliver scalable, rugged, and versatile intelligence from gateway to high-performance edge for real-time insights Lenovo™ expanded its ThinkEdge portfolio with a new generation of AI-driven edge computing solutions, including the compact and reliable ThinkEdge SE10n Gen 2, the AI-ready ThinkEdge SE30n Gen 2, the AI-powerhouse ThinkEdge SE60n Gen 2, and Lenovo’s first industrial all-in-one (AIO) Panel PC, the ThinkEdge SE50a. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223166717/en/ ThinkEdge SE10n Gen 2 As enterprises push intelligence closer to operations to improve resilience, reduce latency, and keep sensitive data local, edge computing has become a critical layer between devices, infrastructure, and cloud. Lenovo’s ThinkEdge solutions are purpose-built, industrial-grade edge systems designed to run reliably in harsh, space-constrained environments where traditional servers or PCs are impractic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom